Clinical trial
Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients…
NCT00148928 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00148928 |
|---|---|
| Title | Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA |
| Official title | A Multicenter, Open-label Phase I/II Trial to Evaluate the Safety and Activity of CPC-P501 Protein Formulated With the Adjuvant AS15 as First-line Treatment in Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms, Prostate |
| Intervention type | Biological |
| Interventions | P501-AS15 vaccine |
| Enrollment | 25 |
| Start date | Mar 1, 2005 |
| Primary completion | Nov 7, 2006 |
| Completion | Nov 7, 2006 |
| First posted | Sep 8, 2005 |
| Last update posted | Jun 2, 2017 |
| Countries | Belgium, France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: